Date: 2012-12-05
Type of information: R&D agreement
Compound: bispecific antibodies using Genmab\'s DuoBody technology
Company: Genmab (Denmark) Kyowa Hakko Kirin (Japan)
Therapeutic area: undisclosed
Type agreement: R&D
Action mechanism: The DuoBody platform is a platform for the discovery and development of bispecific antibodies that may improve antibody therapy of cancer, autoimmune, infectious and central nervous system disease. Bispecific antibodies bind to two different epitopes either on the same, or on different targets (also known as dual-targeting) which may improve the antibodies\' specificity and efficacy in inactivating the disease targets. DuoBody molecules are unique in combining the benefits of bispecificity with the strengths of conventional antibodies which allows DuoBody molecules to be administered and dosed as other antibody therapeutics. Genmab\'s DuoBody platform generates bispecific antibodies via a fast and broadly applicable process which is easily performed at standard bench, as well as commercial, manufacturing scale.
Disease: undisclosed
Details: Genmab has announced a research collaboration with Kyowa Hakko Kirin Co to create bispecific antibodies using Genmab\'s DuoBody technology. If successful, the parties may decide to enter into a license agreement to develop a new DuoBody product. The financial terms of the agreement have not been disclosed. This agreement will not have a material impact on Genmab\'s 2012 financial guidance.
Financial terms:
Latest news:
